Kenpaullone (9-Bromopaullone) is a potent CDK1/2/5 inhibitor that promotes induced regulatory T (iTreg) cell differentiation via enhanced TGFbeta-Smad3 signaling and sustained foxp3 transcription. It is applied in immunology research, including autoimmune disease and cancer immunotherapy studies, utilizing both in vitro and in vivo experimental models.